Russell Investments Group Ltd. Has $16.36 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Russell Investments Group Ltd. raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 288,212 shares of the medical instruments supplier’s stock after acquiring an additional 18,223 shares during the period. Russell Investments Group Ltd. owned about 1.29% of LeMaitre Vascular worth $16,359,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. BluePath Capital Management LLC bought a new stake in shares of LeMaitre Vascular in the third quarter worth $31,000. DekaBank Deutsche Girozentrale bought a new stake in LeMaitre Vascular in the third quarter valued at approximately $38,000. Campbell & CO Investment Adviser LLC raised its stake in LeMaitre Vascular by 78.8% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 5,329 shares of the medical instruments supplier’s stock valued at $290,000 after acquiring an additional 2,349 shares during the period. Panagora Asset Management Inc. bought a new position in LeMaitre Vascular during the third quarter worth $315,000. Finally, Quantbot Technologies LP increased its holdings in shares of LeMaitre Vascular by 709.6% in the third quarter. Quantbot Technologies LP now owns 7,578 shares of the medical instruments supplier’s stock valued at $413,000 after purchasing an additional 6,642 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LMAT. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday. JMP Securities boosted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price target for the stock from $59.00 to $75.00 in a report on Friday, April 26th. KeyCorp assumed coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Barrington Research lifted their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.83.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the sale, the chief executive officer now directly owns 2,187,526 shares in the company, valued at $148,817,393.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of LeMaitre Vascular stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at $148,817,393.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John A. Roush sold 7,500 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total transaction of $517,500.00. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $157,182. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock valued at $7,873,749 over the last three months. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $74.22 on Friday. The firm has a market cap of $1.67 billion, a PE ratio of 55.39, a price-to-earnings-growth ratio of 2.88 and a beta of 0.88. The stock’s fifty day moving average price is $65.93 and its two-hundred day moving average price is $58.71. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The company had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. During the same quarter last year, the business earned $0.27 earnings per share. LeMaitre Vascular’s revenue was up 13.6% on a year-over-year basis. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.66 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were given a dividend of $0.16 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. The ex-dividend date was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 47.76%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.